Mga Batayang Estadistika
| CIK | 811779 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to MultiCell Technologies, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 14, 2019 |
SC 13G/A 1 tv513409sc13ga.htm SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 1) MULTICELL TECHNOLOGIES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 302240403 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 14, 2018 |
MCET / MultiCell Technologies, Inc. / LA JOLLA COVE INVESTORS INC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. ) MULTICELL TECHNOLOGIES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 302240403 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2017 |
MCET / MultiCell Technologies, Inc. / LA JOLLA COVE INVESTORS INC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* MULTICELL TECHNOLOGIES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 302240403 (CUSIP Number) DECEMBER 31ST, 2016 (Date |
|
| January 13, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-10221 MultiCell Technologies, Inc. (Exact name of registrant as specifi |
|
| September 26, 2016 |
The MCIT Presentation by MultiCell Immunotherapeutics, Inc. was released on September 26, 2016. MultiCell Technologies: Exhibit 99.1 - Filed by newsfilecorp.com |
|
| September 26, 2016 |
MultiCell Technologies: Form 8K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 26, 2016 MULTICELL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware (State or othe |
|
| February 16, 2016 |
MCET / MultiCell Technologies, Inc. / LA JOLLA COVE INVESTORS INC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* MULTICELL TECHNOLOGIES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 302240403 (CUSIP Number) DECEMBER 31ST, 2015 (Date |
|
| October 15, 2015 |
10-Q 1 s10195910q.htm FORM 10-Q U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended August 31, 2015. or ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-1 |
|
| July 16, 2015 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended May 31, 2015. or ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, Inc. ( |
|
| July 16, 2015 |
MultiCell Technologies NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 000-000000 NOTIFICATION OF LATE FILING (Check One): ¨Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: May 31, 2015 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q |
|
| April 14, 2015 |
10-Q 1 v40641310q.htm FORM 10-Q U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended February 28, 2015. or ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001 |
|
| April 14, 2015 |
EX-10.1 4 v406413ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 RESEARCH AGREEMENT This RESEARCH AGREEMENT (the “Agreement”), effective as of March 10, 2015 (the “Effective Date”), is made by and between Oxis Biotech, Inc., a Delaware corporation, having a place of business at 1407 North Beverly Drive, Beverly Hills, CA 90210 (“OXIS”) and MultiCell Immunotherapeutics, Inc., a Delaware corporation, having a |
|
| April 14, 2015 |
EX-3.13 2 v406413ex3-13.htm EXHIBIT 3.13 Exhibit 3.13 |
|
| April 14, 2015 |
EX-3.14 3 v406413ex3-14.htm EXHIBIT 3.14 Exhibit 3.14 |
|
| April 14, 2015 |
Exhibit 10.2 LICENSE AGREEMENT THIS LICENSE AGREEMENT (the “Agreement”), effective as of March 10, 2015 (the “Effective Date”), is made by and between Oxis Biotech, Inc., a Delaware corporation, having a place of business at 1407 North Beverly Drive, Beverly Hills, CA 90210 (“OXIS”) and MultiCell Immunotherapeutics, Inc., a Delaware corporation, having a place of business at 68 Cumberland Street, |
|
| March 13, 2015 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 11, 2015 MULTICELL TECHNOLOGIES, INC. |
|
| March 13, 2015 |
Exhibit 99.1 MULTICELL IMMUNOTHERAPEUTICS AND OXIS BIOTECH SIGN ANTIBODY-DRUG CONJUGATE R&D, PRODUCT LICENSE AND COMMERCIALIZATION AGREEMENT WOONSOCKET, RI / March 12, 2015 / PRNewswire / MultiCell Immunotherapeutics, Inc. (MCIT), a majority owned subsidiary of MultiCell Technologies, Inc. [OTC: MCET] announced today it has signed a research & development and product license agreement with Oxis Bi |
|
| March 13, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 v4044648-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 10, 2015 MULTICELL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10221 52-1412493 (State or other jurisdictio |
|
| March 2, 2015 |
Exhibit 21.1 List of Subsidiaries Xenogenics Corporation, a Nevada corporation (95.3% owned) MultiCell Immunotherapeutics, Inc., a Delaware corporation (85.1% owned) |
|
| March 2, 2015 |
AMENDMENT NO. 4 TO FORECLOSURE SALE AGREEMENT Exhibit 10.15 AMENDMENT NO. 4 TO FORECLOSURE SALE AGREEMENT This Amendment No. 4 to the FORECLOSURE SALE AGREEMENT (hereinafter ?Amendment No. 4?) is entered into as of October 3, 2014 by and among Venture Lending & Leasing IV, Inc. (?VLL4?), Venture Lending & Leasing V, Inc. (?VLL5?), Silicon Valley Bank (?SVB?) and Xenogenics Corporation, a Nevada corporation (?Purchaser?). VLL4, VLL5 and SVB ar |
|
| March 2, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K 10-K 1 v40191010k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended November 30, 2014 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-10 |
|
| February 17, 2015 |
MCET / MultiCell Technologies, Inc. / LA JOLLA COVE INVESTORS INC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* MULTICELL TECHNOLOGIES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 302240403 (CUSIP Number) DECEMBER 31ST, 2014 (Date |
|
| February 10, 2015 |
MCET / MultiCell Technologies, Inc. DEFA14A - - FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a 6(e)(2)) ¨ Definitive Proxy State |
|
| February 4, 2015 |
MCET / MultiCell Technologies, Inc. DEFA14A - - DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a 6(e)(2)) ¨ Definitive Proxy State |
|
| January 23, 2015 |
MCET / MultiCell Technologies, Inc. DEFA14A - - DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a 6(e)(2)) ¨ Definitive Proxy State |
|
| December 12, 2014 |
MCET / MultiCell Technologies, Inc. DEF 14A - - DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a 6(e)(2)) x Definitive Proxy State |
|
| December 2, 2014 |
MCET / MultiCell Technologies, Inc. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a 6(e)(2)) ¨ Definitive Proxy State |
|
| October 15, 2014 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended August 31, 2014. or ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, Inc |
|
| July 15, 2014 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended May 31, 2014. ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, Inc. (Exa |
|
| April 14, 2014 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _________________ U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended February 28, 2014. ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, Inc. |
|
| February 28, 2014 |
EX-21.1 4 v367480ex21-1.htm EXHIBIT 21.1 Exhibit 21.1 List of Subsidiaries Xenogenics Corporation, a Nevada corporation (95.3% owned) MultiCell Immunotherapeutics, Inc., a Delaware corporation (67% owned) |
|
| February 28, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 v3702218k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 20, 2014 MULTICELL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10221 52-1412493 (State or other jur |
|
| February 28, 2014 |
v370221ex10-1 - Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing |
|
| February 28, 2014 |
About MultiCell Technologies, Inc. 10-K 1 v36748010k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended November 30, 2013 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-10 |
|
| February 28, 2014 |
Exhibit 10.13 **Confidential Treatment Requested Confidential Treatment Requested Under 17 C.F.R. ?? 200.80(b)(4) and 17 C.F.R. 24b-2 SPONSORED RESEARCH AGREEMENT This Sponsored Research Agreement is made as of the 27th day of September 2013 (?Effective Date?) by and between the following parties: UNIVERSITY HEALTH NETWORK An Ontario not-for-profit corporation incorporated under the University Hea |
|
| February 28, 2014 |
ADDENDUM 2 TO CONVERTIBLE DEBENTURE AND EQUITY INVESTMENT AGREEMENT ADDENDUM 2 TO CONVERTIBLE DEBENTURE AND EQUITY INVESTMENT AGREEMENT This Addendum to Convertible Debenture and Equity Investment Agreement is being entered into this 20th day of February, 2014, by and between MultiCell Technologies, Inc. |
|
| February 13, 2014 |
MCET / MultiCell Technologies, Inc. / LA JOLLA COVE INVESTORS INC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* MULTICELL TECHNOLOGIES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 302240403 (CUSIP Number) DECEMBER 31ST, 2013 (Date |
|
| November 21, 2013 |
Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 15, 2013 MULTICELL TECHNOLOGIES, INC. |
|
| October 15, 2013 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 v35591110q.htm QUARTERLY REPORT U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended August 31, 2013. ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 0 |
|
| October 15, 2013 |
AMENDMENT NO. 3 TO FORECLOSURE SALE AGREEMENT EXHIBIT 10.1 AMENDMENT NO. 3 TO FORECLOSURE SALE AGREEMENT This Amendment No. III to the FORECLOSURE SALE AGREEMENT (this ?Amendment No. 3?) is entered into as of October 11, 2013 by and among Venture Lending & Leasing IV, Inc. (?VLL4?), Venture Lending & Leasing V, Inc. (?VLL5?), Silicon Valley Bank (?SVB?) and Xenogenics Corporation, a Nevada corporation (?Purchaser?). VLL4, VLL5 and SVB are som |
|
| October 8, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a 6(e)(2)) x Definitive Proxy State |
|
| October 3, 2013 |
MultiCell Technologies Expands Scope of Research Agreement for the Treatment of Liver Cancer Exhibit 99.1 MultiCell Technologies Expands Scope of Research Agreement for the Treatment of Liver Cancer WOONSOCKET, R.I., October 2, 2013 /PRNewswire/ - MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) is pleased to announce the signing of a new sponsored research agreement with Anand Ghanekar, M.D., Ph.D, of the University Health Network’s Toronto General Hospital expanding the scope |
|
| October 3, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 27, 2013 MULTICELL TECHNOLOGIES, INC. |
|
| September 26, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a 6(e)(2)) ¨ Definitive Proxy State |
|
| September 12, 2013 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 12, 2013 MULTICELL TECHNOLOGIES, INC. |
|
| September 12, 2013 |
EXHIBIT 16.1 September 12, 2013 Securities and Exchange Commission 450 5th Street NW Washington, DC 20549 Ladies and Gentlemen: We have read the statements of MultiCell Technologies, Inc., included under Item 4.01 of Form 8-K, with respect to this firm’s resignation as the registered independent accounting firm of MultiCell Technologies, Inc. that occurred on September 8, 2013. We agree with the s |
|
| August 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2013 MULTICELL TECHNOLOGIES, INC. |
|
| August 6, 2013 |
MultiCell Technologies and Genisphere Evaluate Targeted Delivery of MCT-485, a Noncoding miRNA for the Treatment of Cancer WOONSOCKET, R. |
|
| August 6, 2013 |
Financial Statements and Exhibits, Other Events - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2013 MULTICELL TECHNOLOGIES, INC. |
|
| July 12, 2013 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended May 31, 2013. ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, Inc. (Exa |
|
| April 15, 2013 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended February 28, 2013. ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, Inc. |
|
| February 28, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K 10-K 1 v33369210k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended November 30, 2012 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-10 |
|
| February 28, 2013 |
CERTIFICATE OF INCORPORATION OF MULTICELL TECHNOLOGIES, INC. CERTIFICATE OF INCORPORATION OF MULTICELL TECHNOLOGIES, INC. WE, THE UNDERSIGNED, in order to form a corporation for the purposes hereinafter stated, under and pursuant to the provisions of the General Corporation Law of the State of Delaware, do hereby certify as follows: FIRST: The name of the corporation is MultiCell Technologies, Inc. SECOND: Its registered office in the State of Delaware is t |
|
| February 28, 2013 |
Exhibit 21.1 List of Subsidiaries Xenogenics Corporation, a Nevada corporation (95.3% owned) MultiCell Immunotherapeutics, Inc., a Delaware corporation (67% owned) |
|
| February 13, 2013 |
MCET / MultiCell Technologies, Inc. / LA JOLLA COVE INVESTORS INC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* MULTICELL TECHNOLOGIES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 302240403 (CUSIP Number) DECEMBER 31ST, 2012 (Date |
|
| October 25, 2012 |
AMENDMENT NO. 2 TO FORECLOSURE SALE AGREEMENT AMENDMENT NO. 2 TO FORECLOSURE SALE AGREEMENT This Amendment No. II to the FORECLOSURE SALE AGREEMENT (this “Amendment No. 2”) is entered into as of October 23, 2012 by and among Venture Lending & Leasing IV, Inc. (“VLL4”), Venture Lending & Leasing V, Inc. (“VLL5”), Silicon Valley Bank (“SVB”) and Xenogenics Corporation, a Nevada corporation (“Purchaser”). VLL4, VLL5 and SVB are sometimes referre |
|
| October 25, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 23, 2012 MULTICELL TECHNOLOGIES, INC. |
|
| October 24, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 19, 2012 MULTICELL TECHNOLOGIES, INC. |
|
| October 24, 2012 |
SETTLEMENT AGREEMENT AND MUTUAL RELEASE SETTLEMENT AGREEMENT AND MUTUAL RELEASE This Settlement Agreement and Mutual Release (“Agreement”), is entered into by and between MultiCell Technologies, Inc. |
|
| October 24, 2012 |
Grant G. Miller Joins Board of MultiCell Technologies Grant G. Miller Joins Board of MultiCell Technologies SAN DIEGO, October 22, 2012 /PRNewswire/ - MultiCell Technologies, Inc. (MCET.OB), a clinical-stage biopharmaceutical company, has added Grant G. Miller to its board of directors. Mr. Miller will replace Mr. Altig who will be stepping down to allow for this appointment. Mr. Miller received his B.A. from Loma Linda University in Riverside, CA an |
|
| October 15, 2012 | ||
| October 15, 2012 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended August 31, 2012. ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, Inc. ( |
|
| September 6, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 6, 2012 MULTICELL TECHNOLOGIES, INC. |
|
| September 6, 2012 |
Scott Lukeman, Ph.D., Joins Board of MultiCell Technologies Scott Lukeman, Ph.D., Joins Board of MultiCell Technologies SAN DIEGO, September 6, 2012 /PRNewswire/ - MultiCell Technologies, Inc. (MCET.OB), a clinical-stage biopharmaceutical company, has added Scott Lukeman, Ph.D., to its board of directors. Dr. Lukeman received his Ph.D. in Pharmacology/Cellular and Molecular Biology from the University of Miami, after earning a B.A. in Natural Sciences from |
|
| August 13, 2012 |
EXHIBIT 3.01 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF MULTICELL TECHNOLOGIES, INC. MultiCell Technologies, inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), Does Hereby Certify: First: The name of the Corporation is MultiCell Technologies, Inc. Second: The date of filing of its |
|
| August 13, 2012 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders 8-K 1 v3212638-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2012 MULTICELL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10221 52-1412493 (State or other jurisdicti |
|
| July 16, 2012 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 For the quarterly period ended May 31, 2012. ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, Inc. |
|
| July 16, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act Of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| June 27, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act Of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 16, 2012 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 For the quarterly period ended February 29, 2012. ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, |
|
| February 28, 2012 |
Exhibit 21.1 List of Subsidiaries MCT Rhode Island Corp., a Rhode Island corporation (wholly owned) Xenogenics Corporation, a Nevada corporation (95.3% owned) MultiCell Immunotherapeutics, Inc., a Delaware corporation (67% owned) |
|
| February 28, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K 10-K 1 v30236110k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x Annual Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended November 30, 2011 ¨ Transition Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-10221 MultiCel |
|
| December 30, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) MULTICELL TECHNOLOGIES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 302240403 (CUSIP Number) December 30, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| October 17, 2011 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 For the quarterly period ended August 31, 2011. ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, In |
|
| October 6, 2011 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 v2366048k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 30, 2011 MULTICELL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10221 52-1412493 (State or other ju |
|
| October 6, 2011 | ||
| August 19, 2011 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 16, 2011 MULTICELL TECHNOLOGIES, INC. |
|
| August 19, 2011 | ||
| July 15, 2011 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 For the quarterly period ended May 31, 2011. ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, Inc. |
|
| July 13, 2011 |
CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF MULTICELL TECHNOLOGIES, INC. EX-3.01 2 v228552ex3-1.htm CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATI CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF MULTICELL TECHNOLOGIES, INC. MultiCell Technologies, inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), Does Hereby Certify: First: |
|
| July 13, 2011 |
8-K 1 v2285528k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 11, 2011 MULTICELL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10221 52-1412493 (State or other jurisdi |
|
| July 13, 2011 |
Exhibit 24 POWER OF ATTORNEY The undersigned, as a Section 16 reporting person of MultiCell Technologies, Inc. |
|
| July 13, 2011 |
Multicell Technologies, Inc. 2004 Equity Incentive Plan Adopted by the Board of Directors on March 3, 2004 Approved by Stockholders on June 16, 2004 Amended by the Board of Directors on March 4, 2005 Approved by the Stockholders on May 18, 2005 Amended by the Board of Directors on June 25, 2009 Approved by the Stockholders on june 25, 2009 Amended by the Board of Directors on May 18, 2010 Approved |
|
| July 11, 2011 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 v2282058k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 11, 2011 MULTICELL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10221 52-1412493 (State or other jurisdiction of incorp |
|
| July 11, 2011 |
PRESS RELEASE MULTICELL AND UNIVERSITY HEALTH NETWORK WILL EVALUATE TWO POTENTIAL THERAPIES FOR LIVER CANCER TREATMENT WOONSOCKET, RI, July 11, 2011 /PRNewsWire/ ? MultiCell Technologies, Inc. |
|
| July 11, 2011 |
EX-10.1 2 v228205ex10-1.htm |
|
| June 15, 2011 |
Exhibit 24 POWER OF ATTORNEY The undersigned, as a Section 16 reporting person of MultiCell Technologies, Inc. |
|
| June 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: o Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| June 15, 2011 |
Exhibit 24 POWER OF ATTORNEY The undersigned, as a Section 16 reporting person of MultiCell Technologies, Inc. |
|
| June 8, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| June 6, 2011 |
June 6, 2011 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 26, 2011 |
PRE 14A 1 v223746pre14a.htm PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as |
|
| April 20, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) MULTICELL TECHNOLOGIES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 302240403 (CUSIP Number) December 10, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| April 14, 2011 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 For the quarterly period ended February 28, 2011. ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, |
|
| March 3, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K 10-K 1 v21332410k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x Annual Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended November 30, 2010 ¨ Transition Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-10221 MultiCell Technolo |
|
| March 3, 2011 |
Exhibit 21.1 List of Subsidiaries MCT Rhode Island Corp., a Rhode Island corporation (wholly owned) Xenogenics Corporation, a Nevada corporation (95.3% owned) MultiCell Immunotherapeutics, Inc., a Delaware corporation (67% owned) |
|
| February 28, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 0-16354 CUSIP Number: 625 44S 20 (Check One): x Form 10-KSB o Form 20-F o Form 11-K o Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: November 30, 2010 x Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition R |
|
| January 3, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) MULTICELL TECHNOLOGIES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 302240403 (CUSIP Number) December 10, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| November 16, 2010 |
MultiCell Technologies, Inc. November 15, 2010 MultiCell Technologies, Inc. November 15, 2010 VIA EDGAR AND OVERNIGHT DELIVERY U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attention: Russell Mancuso Mary Beth Breslin Re: MultiCell Technologies, Inc. Registration Statement on Form SB-2 (File No. 333-124873) Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended, Mu |
|
| November 16, 2010 |
MULTICELL TECHNOLOGIES, INC. November 15, 2010 MULTICELL TECHNOLOGIES, INC. November 15, 2010 VIA EDGAR AND OVERNIGHT DELIVERY U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attention: Russell Mancuso Mary Beth Breslin Re: MultiCell Technologies, Inc. Registration Statement on Form SB-2 (File No. 333-137850) Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (th |
|
| November 15, 2010 |
November 15, 2010 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attenion: Russell Mancuso Mary Beth Breslin Re: MultiCell Technologies, Inc. Application For Withdrawal of the Withdrawal Request filed on November 10, 2010 (for the withdrawal of the Company?s Registration Statement on Form SB-2, file number 333-124873 (the ?Registration Statement?)) for t |
|
| November 15, 2010 |
November 15, 2010 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attenion: Russell Mancuso Mary Beth Breslin Re: MultiCell Technologies, Inc. Application For Withdrawal of the Withdrawal Request filed on November 10, 2010 (for the withdrawal of the Company’s Post-Effective Amendment filed on May 9, 2008 (the “Post-Effective Amendment”) to the Registratio |
|
| November 10, 2010 |
MultiCell Technologies, Inc. November 10, 2010 MultiCell Technologies, Inc. November 10, 2010 VIA EDGAR AND OVERNIGHT DELIVERY U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attention: Russell Mancuso Mary Beth Breslin Re: MultiCell Technologies, Inc. Registration Statement on Form SB-2 (File No. 333-124873) Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended, Mu |
|
| November 10, 2010 |
MultiCell Technologies, Inc. November 10, 2010 MultiCell Technologies, Inc. November 10, 2010 VIA EDGAR AND OVERNIGHT DELIVERY U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attention: Russell Mancuso Mary Beth Breslin Re: MultiCell Technologies, Inc. Registration Statement on Form SB-2 (File No. 333-137850) Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (th |
|
| November 8, 2010 |
Exhibit 99.1 MultiCell Technologies Receives $733,437 Cash Grant Award Under U.S. Government's Qualifying Therapeutic Discovery Project Program WOONSOCKET, R.I., Nov. 2, 2010 /PRNewswire/ - MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) announces it has received cash grant awards under the U.S. government's Qualifying Therapeutic Discovery Project ("QTDP") program. The QTDP program was |
|
| November 8, 2010 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 2, 2010 MULTICELL TECHNOLOGIES, INC. |
|
| October 20, 2010 |
SERIES B CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT EX-10.3 16 v199271ex10-3.htm SERIES B CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT This Series B Convertible Preferred Stock Purchase Agreement (this "Agreement") is made as of October 14, 2010, by and among Xenogenics Corporation, a Nevada corporation (the "Company"), and the Multicell Technologies, Inc., a Delaware corporation (the "Purchaser"). RECITALS WHEREAS, effective September 30, 2010, |
|
| October 20, 2010 |
MULTICELL’S MAJORITY OWNED SUBSIDIARY ACQUIRES BIOABSORBABLE INTERVENTIONAL CARDIOLOGY STENT ASSETS EX-99.1 18 v199271ex99-1.htm PRESS RELEASE MULTICELL’S MAJORITY OWNED SUBSIDIARY ACQUIRES BIOABSORBABLE INTERVENTIONAL CARDIOLOGY STENT ASSETS WOONSOCKET, RI, October 19, 2010 /PRNewsWire/ — MultiCell Technologies, Inc. (OTC Bulletin Board MCET – News) and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corp |
|
| October 20, 2010 |
EX-10.2 3 v199271ex10-2.htm FORECLOSURE SALE AGREEMENT This FORECLOSURE SALE AGREEMENT (the “Agreement”) is entered into as of September , 2010 by and among Venture Lending & Leasing IV, Inc. (“VLL4”), Venture Lending & Leasing V, Inc. (“VLL5”), Silicon Valley Bank (“SVB”) and Xenogenics Corporation, a Nevada corporation (“Purchaser”). VLL4, VLL5 and SVB are sometimes referred to hereinafter colle |
|
| October 20, 2010 |
Completion of Acquisition or Disposition of Assets 8-K 1 v1992718k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 30, 2010 MULTICELL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10221 52-1412493 (State or other jurisdiction of i |
|
| October 20, 2010 |
EX-24.1 17 v199271ex24-1.htm Exhibit 24.1 LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints Anthony Altig the undersigned's true and lawful attorney-in-fact to execute for and on behalf of the undersigned, in the undersigned's capacity as Chief Executive Officer and Chief Financial Officer of Multicell Technologies, Inc. (the "Company") any document necessary in the ordinar |
|
| October 20, 2010 |
EXCLUSIVE LICENSE AGREEMENT XENOGENICS CORPORATION RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY EX-10.1 2 v199271ex10-1.htm EXCLUSIVE LICENSE AGREEMENT Between XENOGENICS CORPORATION And RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY Xenogenics Rutgers 1 EXCLUSIVE LICENSE AGREEMENT THIS LICENSE AGREEMENT (the “Agreement”) is made and is effective as of September 30, 2010, (the “Effective Date”) by and between RUTGERS, THE STATE UNIVERSITY, having its statewide Office of Technology Commercializa |
|
| October 12, 2010 |
U. S. SECURITIES AND EXCHANGE COMMISSION 10-Q 1 v19873010q.htm U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 For the quarterly period ended August 31, 2010. ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 Mult |
|
| September 1, 2010 |
EX-10.1 3 v195818ex10-1.htm Exhibit 10.1 Multicell Technologies, Inc. 2004 Equity Incentive Plan Adopted by the Board of Directors on March 3, 2004 Approved by Stockholders on June 16, 2004 Amended by the Board of Directors on March 4, 2005 Approved by the Stockholders on May 18, 2005 Amended by the Board of Directors on June 25, 2009 Approved by the Stockholders on june 25, 2009 Amended by the Bo |
|
| September 1, 2010 |
CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION MULTICELL TECHNOLOGIES, INC. EX-3.1 2 v195818ex3-1.htm Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF MULTICELL TECHNOLOGIES, INC. Multicell Technologies, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: 1. The name of the Corporation is Multicell Technologies, Inc. The |
|
| September 1, 2010 |
Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits 8-K 1 v1958188k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 26, 2010 MULTICELL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10221 52-1412493 (State or other jurisdiction of inco |
|
| July 15, 2010 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 For the quarterly period ended May 31, 2010. ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, Inc. |
|
| April 26, 2010 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2010 MULTICELL TECHNOLOGIES, INC. |
|
| April 26, 2010 |
MULTICELL TECHNOLOGIES IS GRANTED EUROPEAN PATENT FOR THE TREATMENT OF CANCER EXHIBIT 99.1 PRESS RELEASE MULTICELL TECHNOLOGIES IS GRANTED EUROPEAN PATENT FOR THE TREATMENT OF CANCER WOONSOCKET, RI, April 26, 2010 /PRNewsWire/ ? MultiCell Technologies, Inc. (OTC Bulletin Board MCET ? News) announced today that it has been granted a European patent (EP 1539819B1) covering certain of its therapeutic candidates for the treatment of cancer. Increasing evidence suggests that the |
|
| April 14, 2010 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 For the quarterly period ended February 28, 2010. o Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, |
|
| March 1, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) MULTICELL TECHNOLOGIES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 302240403 (CUSIP Number) December 31, 2009 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 26, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x Annual Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended November 30, 2009. ¨ Transition Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-10221 MultiCell Technologies, Inc. (Exact nam |
|
| February 26, 2010 |
Exhibit 21.1 List of Subsidiaries MCT Rhode Island Corp., a Rhode Island corporation (wholly owned) Xenogenics Corporation, a Nevada corporation (56.4% owned) MultiCell Immunotherapeutics, Inc., a Delaware corporation (67% owned) |
|
| October 14, 2009 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 For the quarterly period ended August 31, 2009. ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, In |
|
| September 21, 2009 |
As filed with the Securities and Exchange Commission on September 21, 2009 As filed with the Securities and Exchange Commission on September 21, 2009 Registration No. |
|
| September 21, 2009 |
EXHIBIT 4.1 Multicell Technologies, Inc. 2004 Equity Incentive Plan Adopted by the Board of Directors on March 3, 2004 Approved by Stockholders on June 16, 2004 Amended by the Board of Directors on March 4, 2005 Approved by the Stockholders on May 18, 2005 Amended by the Board of Directors on June 25, 2009 Approved by the Stockholders on june 25, 2009 Termination Date: March 2, 2014 1. Purposes. ( |
|
| August 7, 2009 |
August 7, 2009 Via EDGAR & Overnight Delivery United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| August 7, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB/A (Amendment No. 1) (X) Annual Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended November 30, 2008. Commission File Number: 001-10221 MultiCell Technologies, Inc. (Name of small business issuer in its charter) DELAWARE (State or other jurisdiction of incorporation or |
|
| August 7, 2009 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 For the quarterly period ended February 28, 2009. ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 Mult |
|
| July 15, 2009 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 For the quarterly period ended May 31, 2009. ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, Inc. |
|
| April 20, 2009 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 For the quarterly period ended February 28, 2009. ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, |
|
| March 19, 2009 |
PRESS RELEASE MULTICELL TECHNOLOGIES SIGNS LIVER STEM CELL R&D AGREEMENT TO DEVELOP PRODUCTS FOR THE STUDY OF LIVER CANCER WOONSOCKET, RI, March 19, 2009 /PRNewsWire/ ? MultiCell Technologies, Inc. |
|
| March 19, 2009 |
Confidential treatment has been requested with respect to certain portions of this exhibit pursuant to a request for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended. |
|
| March 19, 2009 |
Financial Statements and Exhibits, Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 17, 2009 MULTICELL TECHNOLOGIES, INC. |
|
| March 16, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB x Annual Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended November 30, 2008. Commission File Number: 001-10221 MultiCell Technologies, Inc. (Name of small business issuer in its charter) DELAWARE 52-1412493 (State or other jurisdiction of (IRS Employer Identification |
|
| January 22, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) MULTICELL TECHNOLOGIES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 302240403 (CUSIP Number) December 31, 2008 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 14, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT No. 6) MULTICELL TECHNOLOGIES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 302240403 (CUSIP Number) December 31, 2008 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| October 14, 2008 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 For the quarterly period ended August 31, 2008. ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, |
|
| July 15, 2008 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB 10QSB 1 v11989710qsb.htm U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 For the quarterly period ended May 31, 2008. ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 Mu |
|
| May 22, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB/A x Annual Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended November 30, 2007. Commission File Number: 001-10221 MultiCell Technologies, Inc. (Name of small business issuer in its charter) DELAWARE 52-1412493 (State or other jurisdiction of incorporation or organizat |
|
| May 12, 2008 |
MultiCell Technologies, Inc. 68 Cumberland Street, Suite 301 Woonsocket, RI 02895 May 12, 2008 RW 1 v113520rw.htm MultiCell Technologies, Inc. 68 Cumberland Street, Suite 301 Woonsocket, RI 02895 May 12, 2008 BY EDGAR AND OVERNIGHT MAIL U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Mail Stop 6010 Washington, D.C. 20549 Attn: Mary Beth Breslin Re: Multicell Technologies, Inc. Registration Statement on Form SB-2 Initially filed on August 28, 2006 Fil |
|
| May 12, 2008 |
MultiCell Technologies, Inc. 68 Cumberland Street, Suite 301 Woonsocket, RI 02895 May 12, 2008 MultiCell Technologies, Inc. 68 Cumberland Street, Suite 301 Woonsocket, RI 02895 May 12, 2008 BY EDGAR AND OVERNIGHT MAIL U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Mail Stop 6010 Washington, D.C. 20549 Attn: Mary Beth Breslin Re: Multicell Technologies, Inc. Registration Statement on Form SB-2 Initially filed on June 1, 2006 File No. 333-134651 Ladie |
|
| May 12, 2008 |
MultiCell Technologies, Inc. 68 Cumberland Street, Suite 301 Woonsocket, RI 02895 May 12, 2008 MultiCell Technologies, Inc. 68 Cumberland Street, Suite 301 Woonsocket, RI 02895 May 12, 2008 BY EDGAR AND OVERNIGHT MAIL U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Mail Stop 6010 Washington, D.C. 20549 Attn: Mary Beth Breslin Re: Multicell Technologies, Inc. Registration Statement on Form SB-2 Initially filed on April 10, 2007 File No. 333-142002 Lad |
|
| May 9, 2008 |
As filed with the Securities and Exchange Commission on ____________, 2008 As filed with the Securities and Exchange Commission on , 2008 Registration No. 333-137850 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post Effective Amendment No. 1 to FORM SB-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MULTICELL TECHNOLOGIES, INC. (Name of small business issuer in its charter) Delaware 3841 52-1412493 (State or other jurisdiction of inco |
|
| April 24, 2008 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB/A U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB/A x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 For the quarterly period ended February 29, 2008. ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologi |
|
| April 21, 2008 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 For the quarterly period ended February 29, 2008. ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies |
|
| March 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB x Annual Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended November 30, 2007. Commission File Number: 001-10221 MultiCell Technologies, Inc. (Name of small business issuer in its charter) DELAWARE 52-1412493 (State or other jurisdiction of incorporation or organizatio |
|
| February 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT No. 5) MULTICELL TECHNOLOGIES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 302240403 (CUSIP Number) December 31, 2007 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 17, 2008 |
Exhibit 16.1 January 16, 2008 Office of the Chief Accountant, U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, DC 20549-7561 Re: MultiCell Technologies, Inc. Commission File Number: (001-10221) Dear Sirs: We have read Item 4.01 of the Form 8-K, dated January 15, 2008 being filed by MultiCell Technologies, Inc. and are in agreement with the stateme |
|
| January 17, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 15, 2008 MULTICELL TECHNOLOGIES, INC. |
|
| December 26, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 21, 2007 MULTICELL TECHNOLOGIES, INC. |
|
| December 26, 2007 |
MULTICELL TECHNOLOGIES TO INCREASE FOCUS ON THERAPEUTIC CANDIDATES Stephen Chang, Ph. |
|
| October 23, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) MULTICELL TECHNOLOGIES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 302240403 (CUSIP Number) February 28, 2007 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| October 18, 2007 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 For the quarterly period ended August 31, 2007. ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, |
|
| October 15, 2007 |
OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2009 Estimated average burden hours per response ????. |
|
| October 10, 2007 |
MULTICELL TECHNOLOGIES SIGNS WORLDWIDE EXCLUSIVE LICENSE AGREEMENT WITH CORNING INCORPORATED MULTICELL TECHNOLOGIES SIGNS WORLDWIDE EXCLUSIVE LICENSE AGREEMENT WITH CORNING INCORPORATED Corning to Use Cell Lines for Assay Development, Biomarker Identification and ADME/Tox Applications Wednesday, October 10, 2007 Rhode Island-(PR NEWSWIRE)-MultiCell Technologies, Inc. |
|
| October 10, 2007 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 9, 2007 MULTICELL TECHNOLOGIES, INC. |
|
| October 10, 2007 |
LICENSE AND TECHNOLOGY PURCHASE AGREEMENT BETWEEN CORNING AND MULTICELL RELATING TO HEPATOCYTES LICENSE AND TECHNOLOGY PURCHASE AGREEMENT BETWEEN CORNING AND MULTICELL RELATING TO HEPATOCYTES In this Agreement, Corning Incorporated, a New York corporation, having its principal place of business at One Riverfront Plaza, Corning, NY 14831 (hereafter ?CORNING?), and Multicell Technologies, Inc. |
|
| July 20, 2007 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 For the quarterly period ended May 31, 2007. ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiCell Technologies, Inc |
|
| July 19, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 18, 2007 MULTICELL TECHNOLOGIES, INC. |
|
| July 19, 2007 |
MUTUAL TERMINATION AGREEMENT MUTUAL TERMINATION AGREEMENT (the ?Agreement?), dated as of July 18, 2007, by and between MULTICELL TECHNOLOGIES, INC. |
|
| July 19, 2007 |
MultiCell Technologies and Fusion Capital Terminate Common Stock Purchase Agreement MultiCell Technologies and Fusion Capital Terminate Common Stock Purchase Agreement SAN DIEGO-(BUSINESS WIRE)?July 19, 2007 -MultiCell Technologies, Inc. |
|
| July 16, 2007 |
OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2009 Estimated average burden hours per response ????. |
|
| May 30, 2007 |
As filed with the Securities and Exchange Commission on May 30, 2007 Registration No. |
|
| May 2, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 28, 2007 MULTICELL TECHNOLOGIES, INC. |
|
| April 26, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 20, 2007 MULTICELL TECHNOLOGIES, INC. |
|
| April 26, 2007 |
Exhibit 99.1 MultiCell Signs License Agreement with Eisai Japan to Use Fa2N-4 Cell Line for Drug Discovery/ADMETOX Applications SAN DIEGO-MultiCell Technologies, Inc. (OTCBB:MCET - News), has executed a five year licensing agreement with Eisai Co., Ltd. of Tokyo Japan, one of the world’s top 25 pharmaceutical companies. MultiCell has granted Eisai a 5-year nonexclusive license to use MultiCell’s F |
|
| April 26, 2007 |
Item 9.01 Exhibits LICENSE AGREEMENT This License Agreement (the ?Agreement?) is made and entered into as of the 20th day of April 2007 (the ?Effective Date?), by and between MultiCell Technologies, Inc., (?MultiCell?) a corporation organized under the laws of the State of Rhode Island, having a place of business at 701 George Washington Hwy, Lincoln, RI 02865, U.S.A. and Eisai Co., Ltd. (?Eisai?) |
|
| April 17, 2007 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB During the review of our Form 10-KSB, which was filed on March 15, 2007, our independent registered public accounting firm noted several deficiencies related to the presentation of the basic financial statements and the accompanying notes to the financial statements. |
|
| April 10, 2007 |
As filed with the Securities and Exchange Commission on April 10, 2007 Registration No. |
|
| March 15, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB x Annual Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended November 30, 2006. Commission File Number: 001-10221 MultiCell Technologies, Inc. (Name of small business issuer in its charter) DELAWARE (State or other jurisdiction of incorporation or organization) 52-14124 |
|
| March 7, 2007 |
STOCK PLEDGE AGREEMENT This Stock Pledge Agreement is entered into as of February 28, 2007, by and between the individuals listed on Exhibit A (?Pledgors?) and La Jolla Cove Investors, Inc. |
|
| March 7, 2007 |
SECURITIES PURCHASE AGREEMENT Securities Purchase Agreement dated as of February 28, 2007 (this ?Agreement?) by and between MultiCell Technologies, Inc. |
|
| March 7, 2007 |
LA JOLLA COVE INVESTORS, INC. 7817 Herschel Ave., Suite 200 LA JOLLA, CALIFORNIA 92037 TELEPHONE: (415) 409-8703 FACSIMILE: (415) 409-8704 E-MAIL: [email protected] LA JOLLA www.ljcinvestors.com SAN FRANCISCO February 28, 2007 W. Gerald Newmin MultiCell Technologies, Inc. 701 George Washington Highway Lincoln, Rhode Island 02865 Dear Gerald: Reference is made to the $100,000 Convertible Debenture d |
|
| March 7, 2007 |
8-K/A 1 v0677318ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 7, 2007 MULTICELL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10221 52-1412493 (State or other |
|
| March 7, 2007 |
THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR THE SECURITIES LAWS OF ANY STATE, AND IS BEING OFFERED AND SOLD PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH LAWS. |
|
| March 7, 2007 |
February 28, 2007 Dr. Stephen Chang President & CEO MultiCell Technologies, Inc. 701 George Washington Highway Lincoln, RI 02865 Re: Escrow Common Shares Dear Stephen: Reference is made to the 7 ? % Convertible Debenture dated February 28, 2007 (the ?Convertible Debenture?) issued by MultiCell Technologies, Inc. (?Company?) to La Jolla Cove Investors, Inc. (?Holder?). Capitalized terms used herein |
|
| March 7, 2007 |
WARRANT TO PURCHASE COMMON STOCK WARRANT TO PURCHASE COMMON STOCK THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT FOR DISTRIBUTION, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED NEITHER THE WARRANT NOR THE SHARES MAY BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR PURSUANT TO RULE 144 OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. |
|
| March 7, 2007 |
THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR THE SECURITIES LAWS OF ANY STATE, AND IS BEING OFFERED AND SOLD PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH LAWS. |
|
| March 7, 2007 |
February 28, 2007 Dr. Stephen Chang President & CEO MultiCell Technologies, Inc. 701 George Washington Highway Lincoln, Rhode Island 02865 Re: Additional Transaction Dear Stephen: Reference is made to the Convertible Debenture dated February 28, 2007 (the ?Convertible Debenture?) issued by MultiCell Technologies, Inc. (?Company?) to La Jolla Cove Investors, Inc. (?Holder?). All terms used herein a |
|
| March 7, 2007 |
DEBENTURE PURCHASE AGREEMENT This Debenture Purchase Agreement dated as of February 28, 2007 (the ?Agreement?) is made by and between MultiCell Technologies, Inc. |
|
| March 7, 2007 |
REGISTRATION RIGHTS AGREEMENT Registration Rights Agreement dated as of February 28, 2007 (this ?Agreement?) by and between MultiCell Technologies, Inc. |
|
| March 6, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 6, 2007 MULTICELL TECHNOLOGIES, INC. |
|
| March 6, 2007 |
MultiCell Technologies Completes Private Financing Agreement with La Jolla Cove Investors for up to $13 Million to Support Development of Advanced Therapeutics Placement Follows Recent Developmental Milestone to Advance the Company’s Prospective Treatment for Third Most Deadly Cancer SAN DIEGO-(BUSINESS WIRE)-MultiCell Technologies, Inc. |
|
| March 2, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2007 MULTICELL TECHNOLOGIES, INC. |
|
| March 2, 2007 |
March 2, 2007 Office of the Chief Accountant U. S. Securities and Exchange Commission 100 F. Street, N.E. Washington, DC 20549 Re: Multicell Technologies, Inc. SEC File NO. 001-10221 Ladies and Gentlemen: We have read Item 4.02 included in the draft Form 8-K, dated March 2, 2007 (copy attached), of Multicell Technologies, Inc. (the ?Company?), which we understand will be filed with the Securities |
|
| February 28, 2007 |
(Check One): x Form 10-KSB ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR ? Form N-CSR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 14, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT No. 4) MULTICELL TECHNOLOGIES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 302240403 (CUSIP Number) December 31, 2006 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| December 22, 2006 |
Pre-Effective Amendment No. 2 to Form SB-2 Table of Contents As filed with the Securities and Exchange Commission on December 22, 2006 Registration No. 333-134651 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 2 TO FORM SB-2 REGISTRATION STATEMENT Under The Securities Act of 1933 MULTICELL TECHNOLOGIES, INC. (Exact name of Registrant as specified in its chart |
|
| November 20, 2006 |
As filed with the Securities and Exchange Commission on November 20, 2006 Table of Contents As filed with the Securities and Exchange Commission on November 20, 2006 Registration No. |
|
| November 1, 2006 |
Exhibit 10.1 October 26, 2006 Multicell Technologies, Inc. 701 George Washington Highway Lincoln RI 02865 USA Dear Sirs Worldwide Exclusive License Agreement dated December 31st 2005 made between Multicell Technologies. Inc. (?Multicell?) and Amarin Neuroscience Limited (?Amarin?) (the ?Agreement?) We refer to the Agreement, as amended by letter agreement dated June 27, 2006 (?First Amendment Lett |
|
| November 1, 2006 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 26, 2006 MULTICELL TECHNOLOGIES, INC. |
|
| October 25, 2006 |
9,572,327 SHARES OF COMMON STOCK Table of Contents PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-137850 9,572,327 SHARES OF COMMON STOCK This prospectus relates to the offer and sale of up to 9,572,327 shares of the common stock of MultiCell Technologies, Inc. (?MultiCell? or the ?Company?), $0.01 par value per share, by Fusion Capital Fund II, LLC (?Fusion Capital?) from time to time. The prices at which Fusio |
|
| October 18, 2006 |
As filed with the Securities and Exchange Commission on October 18, 2006 Amendment No. 1 to form SB-2 Table of Contents As filed with the Securities and Exchange Commission on October 18, 2006 Registration No. 333-137850 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM SB-2 REGISTRATION STATEMENT Under The Securities Act of 1933 MULTICELL TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) Delaware 3841 52-1412493 |
|
| October 17, 2006 |
(Check One): ¨ Form 10-KSB ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form N-SAR ¨ Form N-CSR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 17, 2006 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB Table of Contents U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 For the quarterly period ended August 31, 2006. ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-10221 MultiC |
|
| October 6, 2006 |
Exhibit 21.1 SUBSIDIARIES Xenogenics Corporation MCT Rhode Island Corporation MultiCell Immunotherapeutics, Inc. |
|
| October 6, 2006 |
As filed with the Securities and Exchange Commission on October 6, 2006 Table of Contents As filed with the Securities and Exchange Commission on October 6, 2006 Registration No. |
|
| October 6, 2006 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Stephen Chang and W. Gerald Newmin, and each of them, as his true and lawful attorney-in-fact and agent with full power of substitution, for him in any and all capacities, to sign any and all amendments to this registration statement (including post-effe |
|
| October 5, 2006 |
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT EX-10.2 3 dex102.htm AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT Exhibit 10.2 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 5, 2006, by and between MULTICELL TECHNOLOGIES, INC., a Delaware corporation, (the “Company”), and FUSION CAPITAL FUND II, LLC (together with it permitted assigns, the “Buye |
|
| October 5, 2006 |
AMENDED AND RESTATED COMMON STOCK PURCHASE AGREEMENT Exhibit 10.1 AMENDED AND RESTATED COMMON STOCK PURCHASE AGREEMENT AMENDED AND RESTATED COMMON STOCK PURCHASE AGREEMENT (the ?Agreement?), dated as of October 5, 2006, by and between MULTICELL TECHNOLOGIES, INC., a Delaware corporation (the ?Company?), and FUSION CAPITAL FUND II, LLC, an Illinois limited liability company (the ?Buyer?). This Agreement amends and restates the Common Stock Purchase A |
|
| October 5, 2006 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2006 MULTICELL TECHNOLOGIES, INC. |
|
| October 5, 2006 |
MultiCell and Fusion Capital Amend and Restate Common Stock Purchase Agreement to provide for $8 million of Equity Funding San Diego, CA - October 5, 2006 - MultiCell Technologies, Inc. |
|
| September 29, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 28, 2006 MULTICELL TECHNOLOGIES, INC. |
|
| September 29, 2006 |
MULTICELL TECHNOLOGIES, INC. CONSULTING AGREEMENT Exhibit 10.2 MULTICELL TECHNOLOGIES, INC. CONSULTING AGREEMENT This Consulting Agreement (?Agreement?) is entered into as of September 28, 2006 by and between Multicell Technologies, Inc. (the ?Company?) and Gerard A. Wills (?Consultant?). This Agreement shall be effective seven (7) days following the execution by Consultant of that certain Separation Agreement and Release between the Company and |
|
| September 29, 2006 |
SEPARATION AGREEMENT AND RELEASE Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (?Agreement?) is made by and between Gerard A. Wills (?Employee?) and MultiCell Technologies, Inc. (?Company?) (collectively referred to as the ?Parties?): RECITALS WHEREAS, Employee provided services to the Company pursuant to an Employment Offer Letter dated December 23, 2005 (the ?Offer Letter?); WHEREAS, the Co |
|
| August 30, 2006 |
425 MARKET STREET SAN FRANCISCO CALIFORNIA 94105-2482 TELEPHONE: 415.268.7000 FACSIMILE: 415.268.7522 WWW.MOFO.COM MORRISON & FOERSTER LLP NEW YORK, SAN FRANCISCO, LOS ANGELES, PALO ALTO, SAN DIEGO, WASHINGTON, D.C. DENVER, NORTHERN VIRGINIA, ORANGE COUNTY, SACRAMENTO, WALNUT CREEK, CENTURY CITY TOKYO, LONDON, BEIJING, SHANGHAI, HONG KONG, SINGAPORE, BRUSSELS August 30, 2006 Writer?s Direct Contac |
|
| August 28, 2006 |
As filed with the Securities and Exchange Commission on August 28, 2006 Form SB-2 Table of Contents As filed with the Securities and Exchange Commission on August 28, 2006 Registration No. |
|
| July 28, 2006 |
MULTICELL TECHNOLOGIES, INC. AMENDED AND RESTATED WARRANT TO PURCHASE COMMON STOCK Exhibit 10.2 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. MULTICELL TECH |
|
| July 28, 2006 |
MultiCell Technologies Announces Resignation of Co-Chairman Anthony Cataldo Exhibit 99.1 NEWS FOR IMMEDIATE RELEASE MultiCell Technologies Announces Resignation of Co-Chairman Anthony Cataldo LINCOLN, R.I. - July 28, 2006 ? MultiCell Technologies Inc. (OTCBB:MCET), a developer of therapeutics for the treatment of degenerative neurological diseases, metabolic and endocrinological disorders, and infectious diseases, today announced that Anthony Cataldo, Co-Chairman, has res |
|
| July 28, 2006 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 25, 2006 MULTICELL TECHNOLOGIES, INC. |
|
| July 28, 2006 |
SEPARATION AGREEMENT AND RELEASE Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (?Agreement?) is made by and between Anthony Cataldo (?Contractor)?) and MultiCell Technologies, Inc. (?Company?) (collectively referred to as the ?Parties?): RECITALS WHEREAS, Contractor provided services to the Company pursuant to a Director and Consulting Agreement; WHEREAS, Contractor signed a Director and Cons |
|
| July 24, 2006 |
As filed with the Securities and Exchange Commission on July 24, 2006 Table of Contents As filed with the Securities and Exchange Commission on July 24, 2006 Registration No. |
|
| July 21, 2006 |
Table of Contents As filed with the Securities and Exchange Commission on July 21, 2006 Registration No. |
|
| July 20, 2006 |
EX-10.1 6 dex101.htm FORM OF SHARES OF SERIES B CONVERTIBLE PREFERRED STOCK AND COMMON STOCK WARRANTS Exhibit 10.1 MultiCell Technologies, Inc. Shares of Series B Convertible Preferred Stock and Common Stock Warrants SUBSCRIPTION AGREEMENT July 14, 2006 Ladies and Gentlemen: MultiCell Technologies, Inc., a Delaware corporation (the “Company”), hereby confirms its agreement with [ ] (the “Purchaser |
|
| July 20, 2006 |
Exhibit 4.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is dated as of July 14, 2006, among [ ], and MultiCell Technologies, Inc., a Delaware corporation (the ?Company?). WHEREAS, on the date hereof, the Holders have purchased from the Company, for aggregate consideration of $[ ], [ ] shares of the Company?s Series B Convertible Preferred Stock (the ?Series |
|
| July 20, 2006 |
EX-4.3 4 dex43.htm CERTIFICATE OF DESIGNATION OF SERIES B CONVERTIBLE PREFERRED STOCK Exhibit 4.3 CERTIFICATE OF DESIGNATION OF SERIES B CONVERTIBLE PREFERRED STOCK OF MULTICELL TECHNOLOGIES, INC. (a Delaware corporation) pursuant to Section 151 of the Delaware General Corporation Law MultiCell Technologies, Inc. (the “Corporation”), a corporation organized and existing under the General Corporati |
|
| July 20, 2006 |
8-K 1 d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 14, 2006 MULTICELL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10221 52-1412493 (State or other jurisdiction of inc |
|
| July 20, 2006 |
WARRANT TO PURCHASE COMMON STOCK Exhibit 4.1 WARRANT TO PURCHASE COMMON STOCK THIS WARRANT AND THE SECURITIES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR THE AVAILABILITY |
|
| July 20, 2006 |
WARRANT TO PURCHASE COMMON STOCK EX-4.2 3 dex42.htm FORM OF WARRANT TO PURCHASE COMMON STOCK (CASH EXERCISE) DATED JULY 14, 2006 Exhibit 4.2 WARRANT TO PURCHASE COMMON STOCK THIS WARRANT AND THE SECURITIES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REG |
|
| July 20, 2006 |
MultiCell Technologies Raises $1.7 Million in Private Placement EX-99.1 7 dex991.htm PRESS RELEASE DATED JULY 20, 2006 Exhibit 99.1 NEWS FOR IMMEDIATE RELEASE MultiCell Technologies Raises $1.7 Million in Private Placement LINCOLN, R.I.—July 20, 2006 — MultiCell Technologies Inc. (OTCBB:MCET), a developer of therapeutics for the treatment of degenerative neurological diseases, metabolic and endocrinological disorders, and infectious diseases, announced that on |
|
| July 17, 2006 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB Form 10QSB Table of Contents U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 for the quarterly period ended May 31, 2006. ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number 001-1022 |
|
| July 5, 2006 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 28, 2006 MULTICELL TECHNOLOGIES, INC. |
|
| July 5, 2006 |
Exhibit 10.1 June 27th 2006 Multicell Technologies, Inc. 701 George Washington Highway Lincoln RI 02865 USA Dear Sirs, Worldwide Exclusive License Agreement dated December 31st 2005 made between Multicell Technologies, Inc. (?Multicell?) and Amarin Neuroscience Limited (?Amarin?) (the ?Agreement?) We refer to the discussions last month between Multicell and Amarin relating to the payment of the su |
|
| June 9, 2006 |
Exhibit 21.1 SUBSIDIARIES Xenogenics Corporation MCT Rhode Island Corporation MultiCell Immunotherapeutics, Inc. |
|
| June 9, 2006 |
As filed with the Securities and Exchange Commission on June 9, 2006 Table of Contents As filed with the Securities and Exchange Commission on June 9, 2006 Registration No. |
|
| June 1, 2006 |
Exhibit 21.1 SUBSIDIARIES Xenogenics Corporation MCT Rhode Island Corporation MultiCell Immunotherapeutics, Inc. |
|
| June 1, 2006 |
Table of Contents As filed with the Securities and Exchange Commission on June 1, 2006 Registration No. |
|
| June 1, 2006 |
Director Compensation (as of May 31, 2006) Exhibit 10.12 Director Compensation (as of May 31, 2006) Each director of the Company receives a per meeting fee of $3,000 for each board meeting attended. The Chairman of the Audit Committee is paid $4,000 per meeting for each Audit committee meeting attended during the year and each committee member receives $1,000 per meeting attended. The Chairman of the Nominating, Corporate Governance and Co |
|
| June 1, 2006 |
[Letterhead of Wilson Sonsini Goodrich & Rosati, P.C.] May 31, 2006 EXHIBIT 5.1 [Letterhead of Wilson Sonsini Goodrich & Rosati, P.C.] May 31, 2006 Multicell Technologies, Inc. 701 George Washington Highway Lincoln, RI 02865 Re: Registration Statement on Form SB-2 Ladies and Gentlemen: We have examined the Registration Statement on Form SB-2 to be filed by you with the Securities and Exchange Commission on or about the date hereof (the ?Registration Statement?) in |
|
| May 26, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 26, 2006 MULTICELL TECHNOLOGIES, INC. |
|
| May 26, 2006 |
MultiCell Technologies Appoints Stephen Chang, Ph.D. as Chief Executive Officer Exhibit 99.1 MultiCell Technologies Appoints Stephen Chang, Ph.D. as Chief Executive Officer SAN DIEGO?(BUSINESS WIRE)?May 26, 2006?.MultiCell Technologies, Inc. (OTCBB: MCET - News) a developer of therapeutics for the treatment of degenerative neurological diseases, metabolic and endocrinological disorders, and infectious diseases, announced today that Stephen M. Chang, Ph.D. has been appointed a |
|
| May 25, 2006 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 25, 2006 MULTICELL TECHNOLOGIES, INC. |
|
| May 25, 2006 |
MultiCell Technologies, Inc. Hosts Annual Stockholder Meeting Exhibit 99.1 MultiCell Technologies, Inc. Hosts Annual Stockholder Meeting Spotlights Recent Progress and Drug Development Pipeline for Drugs to Treat MS, Diabetes and Influenza A SAN DIEGO—(BUSINESS WIRE)—May 25, 2006—MultiCell Technologies, Inc. (OTCBB: MCET—News), a developer of therapeutics for the treatment of degenerative neurological diseases, metabolic and endocrinological disorders, and i |
|
| May 4, 2006 |
EX-10.3 4 dex103.htm WARRANTS FOR THE PURCHASE OF 1,572,327 SHARES OF COMMON STOCK Exhibit 10.3 WARRANT THIS WARRANT (THIS “WARRANT”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAW. NEITHER THIS WARRANT NOR ANY WARRANT SHARES ISSUABLE UPON EXERCISE HEREOF NOR ANY INTEREST OR PARTICIPATION HEREIN OR THEREIN MAY BE SOLD, ASSIGNED, MORTGA |
|
| May 4, 2006 |
Exhibit 10.2 Execution Copy REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of May 3, 2006, by and between MULTICELL TECHNOLOGIES, INC., a Delaware corporation, (the ?Company?), and FUSION CAPITAL FUND II, LLC (together with it permitted assigns, the ?Buyer?). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings |
|
| May 4, 2006 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 3, 2006 MULTICELL TECHNOLOGIES, INC. |
|
| May 4, 2006 |
COMMON STOCK PURCHASE AGREEMENT EX-10.1 2 dex101.htm COMMON STOCK PURCHASE AGREEMENT Exhibit 10.1 EXECUTION COPY COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of May 3, 2006, by and between MULTICELL TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and FUSION CAPITAL FUND II, LLC, an Illinois limited liability company (the “Buyer”). Capitalized terms used herein and not ot |
|
| May 4, 2006 |
MultiCell Enters into $25 Million Common Stock Purchase Agreement EX-99.1 5 dex991.htm PRESS RELEASE Exhibit 99.1 MultiCell Enters into $25 Million Common Stock Purchase Agreement SAN DIEGO – (BUSINESS WIRE) – May 4, 2006 – MultiCell Technologies, Inc. (OTCBB: MCET - News), a developer of therapeutics for the treatment of degenerative neurological disease, metabolic and endocrine disorders, and infectious disease, has entered into a common stock purchase agreeme |
|
| April 14, 2006 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB Table of Contents U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB x Quarterly Report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 for the quarterly period ended February 28, 2006. ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number 001-10221 Mult |
|
| March 30, 2006 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| March 3, 2006 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-KSB Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-KSB x Annual Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended November 30, 2005. Commission File Number 001-10221 MultiCell Technologies, Inc. (Name of small business issuer in its charter) DELAWARE 52-1412493 (State or other jurisdiction of incorporation or organ |
|
| March 1, 2006 |
EXHIBIT 99.1 MultiCell Technologies Announces Audit Committee Conclusion Regarding Accounting for Certain Options; Restatement of Financial Statements for the First Three Quarters of Fiscal 2005, the Interim Periods of Fiscal 2004, and for the Fiscal Year 2004 LINCOLN, R.I.?(BUSINESS WIRE)?Feb. 28, 2006?MultiCell Technologies, Inc. (OTCBB: MCET?News), a developer of therapeutics for the treatment |
|
| March 1, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2006 MULTICELL TECHNOLOGIES, INC. |
|
| March 1, 2006 |
(Check One): UNITED STATES x Form 10-KSB SECURITIES AND EXCHANGE COMMISSION ? Form 20-F Washington, D. |
|
| February 6, 2006 |
Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2006 MULTICELL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-10221 (Commission File |
|
| February 6, 2006 |
MULTICELL TECHNOLOGIES, INC. WARRANT TO PURCHASE COMMON STOCK Exhibit 4.1 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR AN OPINION OF COUNSEL SATISFACTORY TO |
|
| January 23, 2006 |
rrd90789102066.html POWER OF ATTORNEY The undersigned, as a Section 16 reporting person of MultiCell Technologies, Inc. (the "Company"), hereby constitutes and appoints W. Gerald Newmin the undersigned's true and lawful attorney-in-fact to: 1. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his or her discretion determine to be req |
|
| January 12, 2006 |
WORLDWIDE EXCLUSIVE LICENSE AGREEMENT Exhibit 10.14 WORLDWIDE EXCLUSIVE LICENSE AGREEMENT This License Agreement (the "Agreement") is made and entered into as of December 31, 2005 ("Effective Date") by and between Amarin Neuroscience Limited, a company organized under the laws of Scotland whose principal place of business is at Kings Park House, Laurehill Business Park, Polmaise Road, Stirling FK7 9JQ, Scotland, UK ("Amarin"), and Mul |
|
| January 12, 2006 |
As filed with the Securities and Exchange Commission on January 12, 2006 Registration No. |
